StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Latest, FY2021
783
Period ended Dec 31, 2021
Change on a year earlier
+4.1%
752 in FY2020
History
7 years
Since FY2015
Sources
5
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M)Year on yearSource
FY2021Dec 31, 2021783+4.1%Form 10-K (filed 2022-02-18) ↗
FY2020Dec 31, 2020752-15.2%Form 10-K (filed 2022-02-18) ↗
FY2019Dec 31, 2019887-0.6%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018892+7.6%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 2017829+1.0%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 2016821-0.6%Form 10-K (filed 2019-02-27) ↗
FY2015Dec 31, 2015826–Form 10-K (filed 2018-02-16) ↗

Breakdown

What makes up lupron (leuprolide) [legacy through fy21] — worldwide net revenues ($m)

Cite this data

StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M), annual FY2015–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron_ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.